In particular, single-agent pembrolizumab (anti-PD-1) was the first to significantly prolong the progression-free survival (PFS) and overall survival (OS) compared with platinum-based CT in patients with advanced NSCLC and PD-L1 expression ≥50% in the KEYNOTE-024 and KEYNOTE-042 trials, becoming a standard of care in the first-line setting [6,7,8]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.